Modeling based biopharmaceutical company Optimata Ltd. has signed a collaboration agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) for the clinical development of drug candidates for solid tumor cancers.
The agreement is intended to efficiently rescue and redirect the clinical development of discontinued drug candidates, which have been shelved by their pharmaceutical companies, using Optimata’s bio-simulation technology known as the Optimata Virtual Patient (OVP).
Lire la suite »
Anti Boycott Israel blog: tumeurs cancéreuses
Source: article de Gali Weinreb @ Globes